Terbinafine-DRLA terbinafine (as hydrochloride) 250 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

terbinafine-drla terbinafine (as hydrochloride) 250 mg tablet blister pack

dr reddys laboratories australia pty ltd - terbinafine hydrochloride, quantity: 281.25 mg (equivalent: terbinafine, qty 250 mg) - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate - treatment in adults of ringworm (tinea corporis, tinea cruris and tinea pedis) due to infection caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum, where oral therapy is considered appropriate owing to the site, severity or extent of the infection, and the infection is not responsive to topical therapy. onychomycosis in adults (fungal infection of the nail) caused by dermatophyte fungi.

QUETIAPINE Australia - English - Department of Health (Therapeutic Goods Administration)

quetiapine

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 345.396 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

QUETIAPINE Australia - English - Department of Health (Therapeutic Goods Administration)

quetiapine

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 230.264 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; titanium dioxide; hypromellose; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.